Form 4: Eli Lilly Executive Anne E. White Reports Stock Transactions

Anne E. White, an Executive Vice President at Eli Lilly, reported the acquisition of common stock and restricted stock units.

Summary

• Anne E. White, an Executive Vice President at Eli Lilly, reported a transaction on February 12, 2024.
• She acquired 5,363 shares of common stock at a price of $737.26 per share.
• She also acquired 3,269 restricted stock units, each representing a contingent right to receive one share of Eli Lilly common stock.
• Following these transactions, Ms. White directly owns 65,569 shares of common stock and 3,269 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions, with no inherent positive or negative sentiment.

Positives

• The acquisition of shares by an executive could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies.

Comparison to Industry Standards

• Executive stock transactions are a standard practice in publicly traded companies like Eli Lilly, similar to those seen at other pharmaceutical giants such as Pfizer (PFE) and Johnson & Johnson (JNJ).
• The reporting of these transactions via SEC Form 4 is a regulatory requirement, ensuring transparency in insider trading activities, which is consistent across all US listed companies.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholder sentiment, but are unlikely to significantly affect the company's operations or financial performance.

Key Dates

Keywords

Eli Lilly, LLY, stock transaction, insider trading, restricted stock units, executive compensation, SEC Form 4